Essai « parapluie » de phase 2 évaluant l’efficacité de combinaisons d’immunothérapies personnalisées chez des patients atteints d’adénocarcinomes de l’estomac métastatiques ou avancés en rechute
Histologically and/or cytologically documented recurrent advanced/metastatic gastric or gastroesophageal junction adenocarcinomas* previously treated with a platinum and fluoropyrimidine-based regimen.
* The gastric or gastroesophageal junction adenocarcinomas that overexpress HER2 should have previously been treated with trastuzumab, except in the case of contraindication.
Patients must have documented disease progression
Patients who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Accessible tumor lesion (primitive lesion or metastasis) for trial dedicated tumor biopsy.
Main Exclusion Criteria:
Residual toxicity from previous treatment grade ≥1, except for alopecia or peripheral neuropathy grade ≤ 2
Radiotherapy within 28 days before inclusion, except for palliative radiotherapy if patients recovered from all side effects
Congenital risk of bleeding, or acquired coagulopathy, or curative anti-coagulant therapies (except for low molecular weight heparin).
Active digestive bleeding within 3 months before inclusion
Patients pretreated with one of the experimental drugs, other immune checkpoint inhibitor anti-cancer drugs (anti-PD1, anti-PDL1, anti-CTLA4, …), or with ramucirumab.
